Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Camp4 Therapeutics Corp

CAMP · Nasdaq · CIK 0001736730 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

5 qualifying P purchase groups
in the current 180-day scoring window

11 Form 4 transaction lines observed in the same window
6 sales · 0 option, withholding, award, gift or other lines

Last qualifying purchase2026-08-31 · Gold Kelly · $39.6K

WHY NO ACTIVE SIGNAL?

Purchase activityPresent
Recent buying5 qualifying line group(s)
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Schwab Andrew J.Director
▼▼▼▼▼
Gold KellyChief Financial Officer
●●
Tardiff DanielChief Scientific Officer
▼
Young Richard ADirector
●
Maricich YuriChief Medical Officer
●
Mandel-Brehm JoshChief Executive Officer
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS4
PURCHASE CONCENTRATION51%Largest buyer: Gold Kelly · $50.4K
CLUSTER BUYING · 15D4 insidersPeak activity: 2026-08-03–2026-08-03

Roles in the peak window: Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-08-31 · Gold Kelly.

Recent Form 4 activity

5Purchases
6Sales
0Other Form 4 lines
9SEC filings · 365 days
BUYING5 qualifying P line(s) · 180 days
SELLING6 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
+5.3%
3M
-6.5%
6M
-10.5%
12M
—

Volatility & liquidity

Volatility
111.2%
Beta
—
Avg daily value
—

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
-168.5%
Industry
Biotechnology

Market data

Price data up to: 2026-10-04 · Price source: OpenBB/yfinance · From SEC filings: ROE · Fiscal year ended: 2025-12-31 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,459,951
Previous report
992,712
Avg daily volume
284,354
Days to cover
5.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-31Gold KellyPurchase (P)Common Stock10,000USD 3.96USD 39,600SEC filing ↗
2026-08-03Young Richard APurchase (P)Common Stock16,378USD 1.65USD 27,024SEC filing ↗
2026-08-03Maricich YuriPurchase (P)Common Stock6,551USD 1.65USD 10,809SEC filing ↗
2026-08-03Mandel-Brehm JoshPurchase (P)Common Stock6,551USD 1.65USD 10,809SEC filing ↗
2026-08-03Gold KellyPurchase (P)Common Stock6,551USD 1.65USD 10,809SEC filing ↗
2025-09-115AM Opportunities II (GP), LLC; 5AM Opportunities II, L.P.; 5AM Partners VI, LLC; 5AM Partners VII, LLC; 5AM Ventures VI, L.P.; 5AM Ventures VII, L.P.; PARMAR KUSHPurchase (P)Common Stock2,941,176USD 1.53USD 4,499,999SEC filing ↗
2025-09-11Young Richard APurchase (P)Common Stock15,151USD 1.65USD 24,999SEC filing ↗
2025-09-11Nashat AmirPurchase (P)Common Stock1,307,189USD 1.53USD 1,999,999SEC filing ↗
2025-09-11Maricich YuriPurchase (P)Common Stock6,060USD 1.65USD 9,999SEC filing ↗
2025-09-11Mandel-Brehm JoshPurchase (P)Common Stock6,060USD 1.65USD 9,999SEC filing ↗
2025-09-11Gold KellyPurchase (P)Common Stock6,060USD 1.65USD 9,999SEC filing ↗
2025-09-11Chee Brian; Polaris Entrepreneurs' Fund VII, L.P.; Polaris Management Co. VII, L.L.C.; Polaris Partners GP X, L.L.C.; Polaris Partners VII, L.P.; Polaris Partners X, L.P.; SCHULMAN AMY WPurchase (P)Common Stock1,307,189USD 1.53USD 1,999,999SEC filing ↗
2024-10-15Chee Brian; Polaris Entrepreneurs' Fund VII, L.P.; Polaris Management Co. VII, L.L.C.; Polaris Partners GP X, L.L.C.; Polaris Partners VII, L.P.; Polaris Partners X, L.P.; SCHULMAN AMY WPurchase (P)Common Stock909,090USD 11.00USD 9,999,990SEC filing ↗
2024-10-15Northpond Ventures GP, LLC; Northpond Ventures II GP, LLC; Northpond Ventures II, LP; Northpond Ventures III GP, LLC; Northpond Ventures III, LP; Northpond Ventures, LP; Rubin Michael P.Purchase (P)Common Stock763,636USD 11.00USD 8,399,996SEC filing ↗
2024-10-15Enavate Sciences GP, LLC; Everest Aggregator, LPPurchase (P)Common Stock1,363,636USD 11.00USD 14,999,996SEC filing ↗

Form 4 evidence

11 transaction lines in the latest 365-day window; 54 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-31Gold KellyPurchase (P)Common Stock10,000USD 3.96USD 39,600SEC filing ↗
2026-08-27Schwab Andrew J.Sale (S)Common Stock400,000USD 4.04USD 1,616,000SEC filing ↗
2026-08-24Schwab Andrew J.Sale (S)Common Stock10USD 4.50USD 45SEC filing ↗
Show recent Form 4 evidence (11 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-31Gold KellyPurchase (P)Common Stock10,000USD 3.96USD 39,600SEC filing ↗
2026-08-27Schwab Andrew J.Sale (S)Common Stock400,000USD 4.04USD 1,616,000SEC filing ↗
2026-08-24Schwab Andrew J.Sale (S)Common Stock10USD 4.50USD 45SEC filing ↗
2026-08-21Schwab Andrew J.Sale (S)Common Stock32,018USD 4.50USD 144,081SEC filing ↗
2026-08-20Schwab Andrew J.Sale (S)Common Stock114,700USD 4.54USD 520,738SEC filing ↗
2026-08-19Schwab Andrew J.Sale (S)Common Stock45,147USD 4.76USD 214,900SEC filing ↗
2026-08-19Tardiff DanielSale (S)Common Stock1,738USD 4.76USD 8,273SEC filing ↗
2026-08-03Young Richard APurchase (P)Common Stock16,378USD 1.65USD 27,024SEC filing ↗
2026-08-03Maricich YuriPurchase (P)Common Stock6,551USD 1.65USD 10,809SEC filing ↗
2026-08-03Mandel-Brehm JoshPurchase (P)Common Stock6,551USD 1.65USD 10,809SEC filing ↗
2026-08-03Gold KellyPurchase (P)Common Stock6,551USD 1.65USD 10,809SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerCAMP
CIK0001736730
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history54 transaction lines from 2024-10-15 to 2026-08-31
23 P purchase lines · 6 S sale lines · 25 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.